Girish Trikha, MD
Pulmonary Disease · East Syracuse, NYNPI 1437360690
Payments from drug & device makers
Across 254 payments — averaging $153.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Boehringer Ingelheim$14K
- Intuitive Surgical$4K
- GSK$995
- Amgen$429
- Jazz Pharmaceuticals Inc.$395
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$29,01575%
- Travel & lodging$9152%
- Food & beverage$6,17816%
- Education$2,7587%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $17,136 |
| Boehringer Ingelheim | 27 | $14,255 |
| Intuitive Surgical | 7 | $3,639 |
| GSK | 50 | $995 |
| Amgen | 21 | $429 |
| Jazz Pharmaceuticals Inc. | 10 | $395 |
| Regeneron Healthcare Solutions, Inc. | 8 | $280 |
| Sanofi | 8 | $279 |
| Grifols USA, LLC | 11 | $232 |
| Fisher & Paykel Healthcare Inc | 7 | $226 |
| Inspire Medical Systems, Inc. | 3 | $115 |
| Mallinckrodt Hospital Products Inc. | 1 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $97 |
| Insmed, Inc. | 5 | $92 |
| Alk-abello, Inc | 3 | $71 |
| Electromed, Inc. | 3 | $70 |
| Verona Pharma, Inc. | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| Mylan Specialty L.p. | 2 | $59 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $47 |
| Pulmonx Corporation | 2 | $45 |
| Abiomed | 1 | $40 |
| Baxter Healthcare | 1 | $31 |
| Harmony Biosciences LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| United Therapeutics Corporation | 1 | $17 |
| Getinge USA Sales, LLC | 1 | $13 |
| 3b Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,866 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 81 | $1,062,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 753 | $610,969 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $213,839 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 143 | $100,588 |
| NucalaMepolizumab | 15 | $84,059 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $34,803 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 125 | $13,153 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $13,025 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 316 | $8,260 |
| Roflumilast | 24 | $3,355 |
| Azelastine Hcl | 159 | $3,249 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,169 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,149 |
| Advair DiskusFluticasone Propion/Salmeterol | 17 | $2,732 |
| Fluticasone Propionate | 172 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $14,255 | $1,062,03881 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $995 | $746,025876 claims |
| Grifols USA, LLCProlastin C | $232 | $213,83924 claims |
| AstraZenecaBreztri Aerosphere | $17,136 | $100,588143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in East Syracuse
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.